JPWO2020168152A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020168152A5 JPWO2020168152A5 JP2021547473A JP2021547473A JPWO2020168152A5 JP WO2020168152 A5 JPWO2020168152 A5 JP WO2020168152A5 JP 2021547473 A JP2021547473 A JP 2021547473A JP 2021547473 A JP2021547473 A JP 2021547473A JP WO2020168152 A5 JPWO2020168152 A5 JP WO2020168152A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- octan
- bicyclo
- acrylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 206010016654 Fibrosis Diseases 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 230000001575 pathological effect Effects 0.000 claims 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- CLWBZMLZCSEKBX-OUKQBFOZSA-N N-[3-[(E)-3-(dimethylamino)-3-oxoprop-1-enyl]phenyl]-N-[[4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-bicyclo[2.2.2]octanyl]methyl]cyclohexanecarboxamide Chemical compound CN(C(/C=C/C=1C=C(C=CC=1)N(C(=O)C1CCCCC1)CC12CCC(CC1)(CC2)C1=NC(=NO1)C)=O)C CLWBZMLZCSEKBX-OUKQBFOZSA-N 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 2
- -1 bicyclo[1.1.1]pentyl Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- FTVCCQXJSHNLLW-JXMROGBWSA-N methyl (E)-3-[3-[[1-(1-methylindazol-5-yl)-2-oxabicyclo[2.2.2]octan-4-yl]methyl-(1-methylpiperidine-4-carbonyl)amino]phenyl]prop-2-enoate Chemical compound CN1CCC(CC1)C(=O)N(CC12COC(CC1)(CC2)C=1C=C2C=NN(C2=CC=1)C)C=1C=C(C=CC=1)/C=C/C(=O)OC FTVCCQXJSHNLLW-JXMROGBWSA-N 0.000 claims 2
- GBLORKKZXYFKPS-RMKNXTFCSA-N methyl (E)-3-[3-[[1-(1-methylindazol-5-yl)-2-oxabicyclo[2.2.2]octan-4-yl]methyl-(oxane-4-carbonyl)amino]phenyl]prop-2-enoate Chemical compound CN1N=CC2=CC(=CC=C12)C12OCC(CC1)(CC2)CN(C(=O)C1CCOCC1)C=1C=C(C=CC=1)/C=C/C(=O)OC GBLORKKZXYFKPS-RMKNXTFCSA-N 0.000 claims 2
- XDXPUAPVNJFJQB-CMDGGOBGSA-N methyl (E)-3-[3-[[4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-bicyclo[2.2.2]octanyl]methyl-(2-methylpropanoyl)amino]phenyl]prop-2-enoate Chemical compound CC(C)C(N(CC(CC1)(CC2)CCC12C1=NC(C)=NO1)C1=CC=CC(/C=C/C(OC)=O)=C1)=O XDXPUAPVNJFJQB-CMDGGOBGSA-N 0.000 claims 2
- DLIKFMJALNGUHO-VOTSOKGWSA-N methyl (E)-3-[3-[[4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-bicyclo[2.2.2]octanyl]methyl-(oxane-4-carbonyl)amino]phenyl]prop-2-enoate Chemical compound C(=O)(OC)/C=C/C1=CC(N(CC23CCC(CC2)(C2=NC(=NO2)C)CC3)C(=O)C2CCOCC2)=CC=C1 DLIKFMJALNGUHO-VOTSOKGWSA-N 0.000 claims 2
- CRUPKDGDYYWNRS-KPKJPENVSA-N methyl (E)-3-[3-[[4-[4-(dimethylamino)phenyl]-1-bicyclo[2.2.2]octanyl]methyl-(oxane-4-carbonyl)amino]phenyl]prop-2-enoate Chemical compound CN(C1=CC=C(C=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CCOCC1)C=1C=C(C=CC=1)/C=C/C(=O)OC)C CRUPKDGDYYWNRS-KPKJPENVSA-N 0.000 claims 2
- IUWFBZUKDCFQPE-OUKQBFOZSA-N methyl (E)-3-[3-[cycloheptanecarbonyl-[[4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound CC1=NOC(C2(CC3)CCC3(CN(C(C3CCCCCC3)=O)C3=CC=CC(/C=C/C(OC)=O)=C3)CC2)=N1 IUWFBZUKDCFQPE-OUKQBFOZSA-N 0.000 claims 2
- XYJIMLOUDYZGMG-FOCLMDBBSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[(4-phenyl-1-bicyclo[2.2.2]octanyl)methyl]amino]phenyl]prop-2-enoate Chemical compound C1(=CC=CC=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CCCCC1)C=1C=C(C=CC=1)/C=C/C(=O)OC XYJIMLOUDYZGMG-FOCLMDBBSA-N 0.000 claims 2
- MRHIJYVQIKRJHK-LFIBNONCSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[1-(4-methoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl]methyl]amino]phenyl]prop-2-enoate Chemical compound COC1=CC=C(C=C1)C12OCC(CC1)(CC2)CN(C(=O)C1CCCCC1)C=1C=C(C=CC=1)/C=C/C(=O)OC MRHIJYVQIKRJHK-LFIBNONCSA-N 0.000 claims 2
- LCIRWNIQDZOPRJ-DYTRJAOYSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]but-2-enoate Chemical compound C(=C(\C1=CC(N(CC23CCC(C4=NC(=NO4)C)(CC2)CC3)C(=O)C2CCCCC2)=CC=C1)/C)/C(=O)OC LCIRWNIQDZOPRJ-DYTRJAOYSA-N 0.000 claims 2
- VRJSAMVCBYPDEJ-VAWYXSNFSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound O(C(=O)/C=C/C1=CC(N(CC23CCC(C4=NC(=NO4)C)(CC2)CC3)C(=O)C2CCCCC2)=CC=C1)C VRJSAMVCBYPDEJ-VAWYXSNFSA-N 0.000 claims 2
- OMXHRDXFSPDMPE-ZHACJKMWSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-(3-morpholin-4-yl-1,2,4-oxadiazol-5-yl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound O(C(=O)/C=C/C1=CC(N(CC23CCC(C=4ON=C(N5CCOCC5)N=4)(CC2)CC3)C(=O)C2CCCCC2)=CC=C1)C OMXHRDXFSPDMPE-ZHACJKMWSA-N 0.000 claims 2
- SHVGKSDCHMKEGE-WNAAXNPUSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-(4-cyclopropylphenyl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]but-2-enoate Chemical compound C1(CC1)C1=CC=C(C=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CCCCC1)C=1C=C(C=CC=1)/C(=C/C(=O)OC)/C SHVGKSDCHMKEGE-WNAAXNPUSA-N 0.000 claims 2
- KREDIGMOKHWQAG-LICLKQGHSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-(4-cyclopropylphenyl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound C1(CC1)C1=CC=C(C=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CCCCC1)C=1C=C(C=CC=1)/C=C/C(=O)OC KREDIGMOKHWQAG-LICLKQGHSA-N 0.000 claims 2
- DYTARZZFGBZQPK-YYDJUVGSSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-(4-methoxyphenyl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]but-2-enoate Chemical compound COC1=CC=C(C=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CCCCC1)C=1C=C(C=CC=1)/C(=C/C(=O)OC)/C DYTARZZFGBZQPK-YYDJUVGSSA-N 0.000 claims 2
- IDRMZIJGPYDMFF-AZPGRJICSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-(4-morpholin-4-ylphenyl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]but-2-enoate Chemical compound O1CCN(CC1)C1=CC=C(C=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CCCCC1)C=1C=C(C=CC=1)/C(=C/C(=O)OC)/C IDRMZIJGPYDMFF-AZPGRJICSA-N 0.000 claims 2
- LXEVVWAZPJEOBA-VAWYXSNFSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-(5-methyl-1,2,4-oxadiazol-3-yl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound C(=O)(OC)/C=C/C1=CC=CC(N(CC23CCC(C4=NOC(=N4)C)(CC2)CC3)C(=O)C2CCCCC2)=C1 LXEVVWAZPJEOBA-VAWYXSNFSA-N 0.000 claims 2
- BMXHXIUHPIPAIA-RMKNXTFCSA-N methyl (E)-3-[3-[cyclopropanecarbonyl-[[4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound CC1=NOC(C2(CC3)CCC3(CN(C(C3CC3)=O)C3=CC=CC(/C=C/C(OC)=O)=C3)CC2)=N1 BMXHXIUHPIPAIA-RMKNXTFCSA-N 0.000 claims 2
- BFVYIYPSVNHQQM-BSYVCWPDSA-N methyl (E)-3-[3-[cyclopropanecarbonyl-[[4-(4-cyclopropylphenyl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]but-2-enoate Chemical compound C1(CC1)C1=CC=C(C=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CC1)C=1C=C(C=CC=1)/C(=C/C(=O)OC)/C BFVYIYPSVNHQQM-BSYVCWPDSA-N 0.000 claims 2
- KQJOCHSBQGSUNJ-VGOFMYFVSA-N methyl (E)-3-[3-[cyclopropanecarbonyl-[[4-(4-propan-2-ylphenyl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound C(C)(C)C1=CC=C(C=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CC1)C=1C=C(C=CC=1)/C=C/C(=O)OC KQJOCHSBQGSUNJ-VGOFMYFVSA-N 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- PZGWYVQYEPHLTQ-LFIBNONCSA-N (E)-3-[3-[cyclohexanecarbonyl-[[4-[4-(dimethylamino)phenyl]-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoic acid Chemical compound CN(C1=CC=C(C=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CCCCC1)C=1C=C(C=CC=1)/C=C/C(=O)O)C PZGWYVQYEPHLTQ-LFIBNONCSA-N 0.000 claims 1
- WSNQQNVQUXEUPX-UHFFFAOYSA-N 5-(1-bicyclo[2.2.2]octanyl)-3-methyl-1,2,4-oxadiazole Chemical compound C1C2(C3=NC(=NO3)C)CCC(C1)CC2 WSNQQNVQUXEUPX-UHFFFAOYSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001587 cholestatic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- CNVURZUCTASLGW-OUKQBFOZSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[1-[4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-bicyclo[2.2.2]octanyl]ethyl]amino]phenyl]prop-2-enoate Chemical compound C(=O)(OC)/C=C/C1=CC(N(C(C23CCC(CC2)(C2=NC(C)=NO2)CC3)C)C(=O)C2CCCCC2)=CC=C1 CNVURZUCTASLGW-OUKQBFOZSA-N 0.000 claims 1
- TXGFQBKOECKEBC-LFIBNONCSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-(4-methoxyphenyl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound COC1=CC=C(C=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CCCCC1)C=1C=C(C=CC=1)/C=C/C(=O)OC TXGFQBKOECKEBC-LFIBNONCSA-N 0.000 claims 1
- GCJBWJJTRLJXPY-XNTDXEJSSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-(4-morpholin-4-ylphenyl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound COC(=O)/C=C/C1=CC(=CC=C1)N(CC23CCC(CC2)(CC3)C4=CC=C(C=C4)N5CCOCC5)C(=O)C6CCCCC6 GCJBWJJTRLJXPY-XNTDXEJSSA-N 0.000 claims 1
- CBLBTOVGRKJQDR-SFQUDFHCSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-(4-propan-2-ylphenyl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound COC(\C=C\C1=CC(=CC=C1)N(C(=O)C1CCCCC1)CC12CCC(CC1)(CC2)C1=CC=C(C=C1)C(C)C)=O CBLBTOVGRKJQDR-SFQUDFHCSA-N 0.000 claims 1
- BSTCSVVVYCMKAR-SFQUDFHCSA-N methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-[4-(dimethylamino)phenyl]-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound CN(C1=CC=C(C=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CCCCC1)C=1C=C(C=CC=1)/C=C/C(=O)OC)C BSTCSVVVYCMKAR-SFQUDFHCSA-N 0.000 claims 1
- HLFHAWDSZCZJQS-LHHJGKSTSA-N methyl (E)-3-[3-[cyclopropanecarbonyl-[[4-(4-cyclopropylphenyl)-1-bicyclo[2.2.2]octanyl]methyl]amino]phenyl]prop-2-enoate Chemical compound C1(CC1)C1=CC=C(C=C1)C12CCC(CC1)(CC2)CN(C(=O)C1CC1)C=1C=C(C=CC=1)/C=C/C(=O)OC HLFHAWDSZCZJQS-LHHJGKSTSA-N 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806047P | 2019-02-15 | 2019-02-15 | |
| US62/806,047 | 2019-02-15 | ||
| PCT/US2020/018217 WO2020168152A2 (en) | 2019-02-15 | 2020-02-14 | Substituted amide compounds useful as farnesoid x receptor modulators |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022519769A JP2022519769A (ja) | 2022-03-24 |
| JP2022519769A5 JP2022519769A5 (https=) | 2022-12-16 |
| JPWO2020168152A5 true JPWO2020168152A5 (https=) | 2022-12-16 |
| JP7449300B2 JP7449300B2 (ja) | 2024-03-13 |
Family
ID=70057213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547473A Active JP7449300B2 (ja) | 2019-02-15 | 2020-02-14 | ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12030835B2 (https=) |
| EP (1) | EP3924329A2 (https=) |
| JP (1) | JP7449300B2 (https=) |
| KR (1) | KR102883856B1 (https=) |
| CN (1) | CN113677659B (https=) |
| AU (1) | AU2020221371A1 (https=) |
| BR (1) | BR112021015930A2 (https=) |
| EA (1) | EA202192244A1 (https=) |
| IL (1) | IL285557A (https=) |
| MX (1) | MX2021009564A (https=) |
| SG (1) | SG11202108798XA (https=) |
| WO (1) | WO2020168152A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7465883B2 (ja) * | 2019-02-15 | 2024-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993013101A1 (fr) | 1991-12-27 | 1993-07-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro |
| WO1998017276A1 (en) | 1996-10-25 | 1998-04-30 | Merck & Co., Inc. | Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists |
| US7319104B2 (en) | 2002-03-01 | 2008-01-15 | Smithkline Beecham Corporation | hPPARs activators |
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| WO2004046162A2 (en) | 2002-11-14 | 2004-06-03 | The Scripps Research Institute | Non-steroidal fxr agonists |
| WO2006006490A1 (ja) | 2004-07-08 | 2006-01-19 | Ono Pharmaceutical Co., Ltd. | スピロ化合物 |
| PL2402002T3 (pl) | 2005-04-08 | 2018-11-30 | Ptc Therapeutics, Inc. | Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop |
| WO2007076260A2 (en) | 2005-12-19 | 2007-07-05 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| WO2008011130A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
| CL2007003035A1 (es) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| EP2108017A2 (en) | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| AU2008223348A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| MX2009013946A (es) | 2007-07-02 | 2010-03-10 | Glaxosmithkline Llc | Agonistas del receptor de farnesoide x. |
| WO2009009059A1 (en) | 2007-07-09 | 2009-01-15 | Biogen Idec Ma Inc. | Spiro compounds as antagonists of tgf-beta |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| CN101910151A (zh) | 2007-10-22 | 2010-12-08 | 先灵公司 | 双环杂环衍生物及其作为gpr119活性调节剂的用途 |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| US20110230493A1 (en) | 2008-11-21 | 2011-09-22 | Pfizer Inc. | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors |
| EP2454243A2 (en) | 2009-07-15 | 2012-05-23 | Merck Serono SA | Tetrazole derivatives |
| US8440710B2 (en) | 2009-10-15 | 2013-05-14 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
| EP2655368A1 (en) | 2010-12-20 | 2013-10-30 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| IN2014DN09346A (https=) | 2012-06-13 | 2015-07-17 | Hoffmann La Roche | |
| EP2903985A1 (en) | 2012-10-03 | 2015-08-12 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
| US9567301B2 (en) | 2012-11-02 | 2017-02-14 | Dana-Farber Cancer Institute, Inc. | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors |
| WO2014113485A1 (en) | 2013-01-15 | 2014-07-24 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| JP6333372B2 (ja) | 2013-07-09 | 2018-05-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤の組み合わせ |
| EP3116851B1 (en) * | 2014-03-13 | 2023-07-26 | Salk Institute for Biological Studies | Analogs of fexaramine and methods of making and using |
| WO2015172747A1 (en) | 2014-05-16 | 2015-11-19 | Zhaoyin Wang | Spirocyclic molecules as mth1 inhibitors |
| WO2016039734A1 (en) | 2014-09-10 | 2016-03-17 | Halliburton Energy Services, Inc. | Perforating gun with integrated retaining system |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| MX2017008057A (es) | 2014-12-18 | 2017-09-28 | Novartis Ag | Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales. |
| CN106146483A (zh) | 2015-04-23 | 2016-11-23 | 上海迪诺医药科技有限公司 | 杂环类法尼酯衍生物x受体调节剂 |
| EP3350164A4 (en) * | 2015-09-16 | 2019-03-27 | Metacrine, Inc. | FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF |
| US10703712B2 (en) * | 2015-09-16 | 2020-07-07 | Metacrine, Inc. | Farnesoid X receptor agonists and uses thereof |
| WO2017078927A1 (en) | 2015-11-06 | 2017-05-11 | Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| CN106946867B (zh) | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| CN107021958A (zh) | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| WO2017133521A1 (zh) | 2016-02-01 | 2017-08-10 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| MX384205B (es) | 2016-02-22 | 2025-03-14 | Novartis Ag | Metodos para usar agonistas de fxr. |
| ES2862194T3 (es) | 2016-02-22 | 2021-10-07 | Novartis Ag | Métodos para usar agonistas del FXR |
| CN109640987B (zh) | 2016-03-16 | 2022-12-02 | 库拉肿瘤学公司 | Menin-mll的桥联双环抑制剂及使用方法 |
| WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| AR108711A1 (es) | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
| MX385718B (es) | 2016-06-13 | 2025-03-18 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4). |
| CN108430998B (zh) | 2016-09-28 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | 氮杂双环衍生物及其制备方法和用途 |
| CN106632294A (zh) | 2016-12-15 | 2017-05-10 | 宁波百纳西药业有限公司 | 一种螺环化合物及其药物用途 |
| WO2018170165A1 (en) * | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| WO2018170167A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| US20200131129A1 (en) | 2017-03-15 | 2020-04-30 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| CA3055990A1 (en) * | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| JP7258763B2 (ja) * | 2017-03-15 | 2023-04-17 | メタクリン，インク． | ファルネソイドｘ受容体アゴニストおよびその使用 |
| PE20201170A1 (es) | 2017-11-01 | 2020-10-28 | Bristol Myers Squibb Co | Compuestos biciclicos en puente como moduladores del receptor farnesoide x |
| EA202190661A1 (ru) | 2018-09-18 | 2021-08-13 | Метакрайн, Инк. | Агонисты фарнезоидного х-рецептора для лечения заболевания |
-
2020
- 2020-02-14 AU AU2020221371A patent/AU2020221371A1/en not_active Abandoned
- 2020-02-14 MX MX2021009564A patent/MX2021009564A/es unknown
- 2020-02-14 BR BR112021015930-4A patent/BR112021015930A2/pt not_active Application Discontinuation
- 2020-02-14 US US17/431,091 patent/US12030835B2/en active Active
- 2020-02-14 SG SG11202108798XA patent/SG11202108798XA/en unknown
- 2020-02-14 EA EA202192244A patent/EA202192244A1/ru unknown
- 2020-02-14 JP JP2021547473A patent/JP7449300B2/ja active Active
- 2020-02-14 CN CN202080028268.XA patent/CN113677659B/zh active Active
- 2020-02-14 EP EP20715505.2A patent/EP3924329A2/en active Pending
- 2020-02-14 KR KR1020217029611A patent/KR102883856B1/ko active Active
- 2020-02-14 WO PCT/US2020/018217 patent/WO2020168152A2/en not_active Ceased
-
2021
- 2021-08-11 IL IL285557A patent/IL285557A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020123827A5 (https=) | ||
| RU2498983C2 (ru) | Соединения фениламинопиримидина и их применения | |
| JP6964096B2 (ja) | ３−オキソ−２，６−ジフェニル−２，３−ジヒドロピリダジン−４−カルボキサミド類 | |
| RU2361860C2 (ru) | Новые замещенные 3-сера-индолы | |
| ES2539256T3 (es) | Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos | |
| JP2004502670A5 (https=) | ||
| JP2011513367A5 (https=) | ||
| JP2009519965A5 (https=) | ||
| JP2005509024A5 (https=) | ||
| JP2023501599A (ja) | Ｌｐａ受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用 | |
| JP2014528464A5 (https=) | ||
| WO2015008230A1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| JP2007523142A5 (https=) | ||
| JPWO2020092196A5 (https=) | ||
| JP2014523400A (ja) | 芳香族アミド類およびそれらの使用 | |
| ES2533095T3 (es) | Agonistas de receptores de esfingosina-1-fosfato | |
| WO2016069978A1 (en) | AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORγT | |
| JP2006525990A5 (https=) | ||
| JP2020502213A5 (https=) | ||
| JPWO2020168152A5 (https=) | ||
| JPWO2021110805A5 (https=) | ||
| JPWO2021186185A5 (https=) | ||
| JP2020527149A5 (https=) | ||
| RU2014122487A (ru) | 1-пиридазинил-гидроксиимино-3-фенил-пропаны в качестве агонистов сопряженного с g-белком рецептора желчных кислот gpbar1 | |
| JPWO2023152698A5 (https=) |